DermTech, Inc.

DermTech, Inc. (Nasdaq: DMTK) is a precision dermatology company focused on non-invasive genomic diagnostics for skin conditions, most notably its adhesive patch-based testing platform for melanoma risk stratification. The company filed this Form 10-Q with the SEC on August 14, 2017, accession number 0001144204-17-043204, reflecting its status as a publicly reporting entity in the molecular diagnostics and dermatology sector. DermTech operates at the intersection of genomics and dermatological care, developing tools designed to reduce unnecessary biopsies and improve early detection outcomes. To access DermTech's full filing history, financial data, and related transaction intelligence, sign up for a SpacDesk account at spacdesk.com.